B-MS exec pleads guilty to anti-trust dealings

6 April 2009

A former senior executive of Bristol-Myers Squibb, Andrew Bodnar, has pleaded guilty for his role in the US drug major's dishonest dealings  with the federal government relating to a patent deal involving Plavix  (clopidogrel), a blockbuster blood-thinner developed with  Sanofi-Aventis.

The plea follows B-MS' June 11, 2007, agreement to plead guilty and pay  a $1.0 million criminal fine for misleading the US government about a  deal that threatened to reduce competition and could have lowered the  cost of the drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight